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Abstract
Background and Aims: Diagnostic values of FibroTest (FT) for hepatic fibrosis have rarely been assessed in Asian chronic
hepatitis B (CHB) patients. We aimed to validate its diagnostic performances in comparison with liver stiffness (LS).
Methods: From 2008 to 2010, 194 CHB patients who underwent liver biopsies along with FT and transient elastography
were prospectively enrolled. Fibrosis stage was assessed according to the Batts and Ludwig system.
Results: To predict significant fibrosis (F$2), advanced fibrosis (F$3), and cirrhosis (F = 4), areas under receiver operating
characteristic curves (AUROCs) of FT were 0.903, 0.907, and 0.866, comparable to those of LS (0.873, 0.897, and 0.910,
respectively). Optimized cutoffs of FT to maximize sum of sensitivity and specificity were 0.32, 0.52, and 0.68 for F$2, F$3,
and F= 4, while those of LS were 8.8, 10.2, and 14.1 kPa, respectively. According to FT and LS cutoffs, 123 (63.4%) and 124
(63.9%) patients were correctly classified consistent with histological fibrosis (F1, F2, F3, and F4), respectively. Overall
concordance between each fibrosis stage estimated by FT and LS was observed in 111 patients, where 88 were correctly
classified with histological results. A combination formula adding LS to FT (LS+FT) showed similar AUROC levels (0.885,
0.905, and 0.915), while another multiplying LS by FT (LS6FT) showed the best AUROCs (0.941, 0.931, and 0.929 for F$2,
F$3, and F4, respectively).
Conclusions: FT provides good fibrosis prediction, with comparable outcomes to LS in Asian CHB patients. FT substantially
reduces need for liver biopsy, especially when used in combination with LS.
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Introduction
Accurate assessment of the severity of liver fibrosis in patients
with chronic hepatitis B (CHB) is necessary not only for predicting
the long-term clinical course, but also for determining whether and
when to begin antiviral therapy. Most recent guidelines on the
management of CHB have proposed that the presence of
significant fibrosis with detection of serum hepatitis B virus
(HBV) DNA is a clear indication to commence antiviral therapy,
because maintenance of viral suppression can reduce liver-related
complications in patients with CHB who have significant fibrosis
or cirrhosis [1,2,3]. Conversely, the absence of significant fibrosis
in patients with low levels of circulating virus is an indication to
monitor rather than initiate expensive and potentially long-lasting
antiviral therapy. Furthermore, as patients with cirrhosis should be
followed-up closely for the development of hepatocellular
carcinoma and other complications associated with hepatic
decompensation, including gastroesophageal varices, assessment
of fibrotic burden in patients with CHB has become an important
clinical issue for physicians [1,4].
To date, liver biopsy has been the gold standard for assessing
liver fibrosis. It is often limited, however, by its invasiveness, cost,
risk of complications, poor acceptance, lack of availability of
expert practitioners, and intra/inter-observer variability [5,6].
These drawbacks make sequential liver biopsies unfeasible,
especially when repeated examinations are required to monitor
the response to antiviral or antifibrosis treatment. Consequently,
these limitations have stimulated the researches for noninvasive
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approaches, such as the aspartate aminotransferase (AST)-to-
platelet ratio index (APRI) [7], AST-alanine aminotransferase
(ALT) ratio [8], Forns test [9], and FibroTest (FT; BioPredictive,
Paris, France) [10], all of which combine several biochemical
parameters [11,12,13].
Recently, liver stiffness (LS) value assessed by transient
elastography (TE; FibroScanH; Echosens, Paris, France), which
relies on calculating liver elasticity from the velocity of a low
frequency elastic wave transmitted through the liver, has been
introduced as a noninvasive surrogate for liver biopsy in the
assessment of liver fibrosis [14,15,16]. As TE was first developed in
France, most studies on its benefits have been performed in
European countries where chronic hepatitis C (CHC) is prevalent.
However, due to vigorous efforts to apply TE to Asian subjects
with CHB, it has now been shown to have acceptable accuracy in
diagnosing liver fibrosis and cirrhosis in these subjects [17].
Meanwhile, Poynard et al. [10] in 2001, proposed a scoring
algorithm using a panel of five biochemical markers, i.e., FT,
including a2-macroglobulin, apolipoproteinA1, haptoglobin, c-
glutamyl-transpeptidase (GGT), and total bilirubin for assessment
of liver fibrosis, adjusted by age and gender. FT has been studied
extensively as a surrogate marker for liver biopsy. It was initially
validated primarily in Caucasian populations with CHC and the
results showed a good correlation with liver fibrosis stage
[18,19,20]. However, in contrast to TE, only a few studies have
been reported to date in patients with CHB [21,22,23,24,25]. In
particular, the investigation focusing Asian population with CHB
has been extremely scarce.
The present study was performed to prospectively validate the
diagnostic value of FT in Asian populations with CHB in
comparison with TE, to define optimized thresholds for predicting
liver fibrosis, and to investigate the performance of the combined
use of FT and LS.
Materials and Methods
1. Patients
Consecutive patients with CHB who underwent liver biopsy
along with FT and TE on the same day at Severance Hospital,
Yonsei University College of Medicine, Seoul, Korea, between
July 2008 and June 2010, were considered eligible for this study.
Liver biopsy was performed to assess the severity of fibrosis and
inflammation prior to treatment.
The exclusion criteria were as follows: previous history of
antiviral therapy; history of hepatocellular carcinoma (HCC)
treatment at the time of liver biopsy; diagnosis of malignancy other
than HCC during follow-up; liver biopsy specimen shorter than
20 mm; coinfection with human immunodeficiency virus; invalid
LS values with fewer than ten successful acquisitions, a success rate
of less than 60%, or interquartile range (IQR)/median value ratio
(IQR/M) greater than 0.3; alcohol ingestion in excess of 40 g/day
for more than 5 years; or right-sided heart failure.
The study was performed in accordance with the ethical
guidelines of the 1975 Declaration of Helsinki. Written informed
consent was obtained from each participant or responsible family
member after possible complications of the diagnostic procedures
had been fully explained. This study was approved by the
Institutional Review Board of Severance Hospital.
Figure 1. Flow chart describing the selection of the study population. Based on the exclusion criteria, 194 subjects were finally recruited for
analyses.
doi:10.1371/journal.pone.0035825.g001
Table 1. Baseline characteristics (n = 194).
Characteristics Value
Demographic data
Age (years) 46.7614.7
Male gender, no. (%) 119 (61.3)
Body mass index (kg/m2) 23.462.8
Laboratory data
Serum albumin (g/dL) 4.7561.37
Total bilirubin (mg/dL) 1.1660.90
Aspartate aminotransferase (IU/L) 44.1628.3
Alanine aminotransferase (IU/L) 58.4627.1
Prothrombin time (%) 93.1613.3
Platelet count (109/L) 179.3671.2
Biopsy length (mm) 21.360.7
Liver stiffness (kPa) 14.269.5
FibroTest 0.5360.29
Fibrosis stage, no. (%)
F0 0 (0)
F1 30 (15.5)
F2 50 (25.7)
F3 39 (20.1)
F4 75 (38.7)
Values were expressed as mean 6 standard deviation, unless indicated
otherwise.
doi:10.1371/journal.pone.0035825.t001
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2. Serum biochemical tests and FT score calculation
All laboratory data including specific parameters for calculating
FT score including a2-macroglobulin level, apolipoprotein A1
level, haptoglobin level, c-GGT level, and total bilirubin level were
obtained on the same day as TE and liver biopsy. FT score was
computed on the BioPredictive website (www.biopredictive.com)
as follows: f = 4.4676log[a2-macroglobulin (g/L)]21.3576lo-
g[haptoglobin (g/L)]+1.0176log[c-GGT (IU/L)]+0.02816[age
(in years)]+1.7376log[bilirubin (mmol/L)]21.1846[apolipopro-
tein A1 (g/L)]+0.3016sex (female = 0, male = 1)25.540.
3. Assessment of LS values
TE was performed by one well-trained technician using
FibroScanH on the same day as FT. Details of the technique
and examination procedure were reported previously [26,27]. The
results were expressed in kilopascals (kPa). IQR was defined as an
index of intrinsic variability of LS values corresponding to the
interval of LS results containing 50% of the valid measurements
between the 25th and 75th percentiles. The median value was
considered representative of the elastic modulus of the liver. Only
procedures with at least 10 valid measurements, a success rate of at
least 60%, and an IQR-to-median ratio ,30% were considered
reliable.
The TE operator was blinded to patients’ clinical and
laboratory data.
4. Liver biopsy examination
Percutaneous liver biopsy was performed using a 16G
disposable needle immediately after TE. The liver biopsy
specimens were fixed in formalin and embedded in paraffin.
Figure 2. Box plots of LS (A) and FT (B) according to fibrosis stage. Boxes and horizontal lines within boxes represent interquartile ranges
(IQRs) and median values, respectively. The upper and lower whiskers indicate 75th percentile plus 1.5 IQR and 25th percentile minus 1.5 IQR,
respectively. o, mild outlier: a value more than 75th percentile plus 1.5 IQR, but less than 75th percentile plus 3.0 IQR. *, extreme outlier: a value more
than 75th percentile plus 3 IQR.
doi:10.1371/journal.pone.0035825.g002
Figure 3. Receiver operating characteristic (ROC) curves for LS and FT in the diagnosis of significant fibrosis ($F2, A), advanced
fibrosis ($F3, B), and cirrhosis (F =4, C).
doi:10.1371/journal.pone.0035825.g003
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Then, sections 4 mm thick were stained with hematoxylin and
eosin (H&E) and Masson’s trichrome. All liver tissue samples were
evaluated by an experienced hepatopathologist (YN Park) who was
blinded to the patients’ clinical histories. Specimens that were
shorter than 20 mm and considered by the pathologists to be
unsuitable for fibrosis assessment were excluded from the analysis.
Liver histology was evaluated semiquantitatively according to the
Batts and Ludwig scoring system [28]. Fibrosis was staged on a 0–
4 scale: F0, no fibrosis; F1, portal fibrosis; F2, periportal fibrosis;
F3, septal fibrosis; and F4, cirrhosis. Significant fibrosis was
defined as F2 or more, advanced fibrosis as F3 or more, and
cirrhosis as F4.
5. Statistical analyses
The major goals of this study were to prospectively validate the
diagnostic performance of FT for detection of the presence of
histological significant fibrosis, advanced fibrosis, and cirrhosis in
comparison with LS and to suggest optimal cutoff values in
patients with CHB. To assess the diagnostic performance of each
noninvasive index, receiver operating characteristic (ROC) curves
were constructed and the areas under the ROC curves (AUROCs)
were calculated. Then, to evaluate the usefulness of the
noninvasive method, the sensitivity, specificity, positive predictive
value (PPV), and negative predictive value (NPV) were determined
from the ROC curves. Furthermore, we evaluated the usefulness
of combined use of FT and LS as a surrogate marker for liver
biopsy.
Statistical analyses were performed using SAS software version
9.1.3 (SAS, Cary, NC). In all analyses, p,0.05 was taken to
indicate statistical significance.
Results
1. Patients baseline characteristics
A total of 350 consecutive patients were screened for possible
inclusion in the study. Based on the exclusion criteria, a total of
194 patients (mean age 46.7 years, 119 male) were analyzed
(Figure 1).
The patients’ characteristics are summarized in Table 1. The
mean ALT level was 58.4 IU/L, while the mean AST level was
44.1 IU/L. The mean LS and FT were 14.2 kPa and 0.53,
respectively. The mean length and the median number of
fragments of liver biopsy samples were 21.3 mm and 2,
respectively. The fibrosis stages were F0 in 0 (0%) patients, F1
in 30 (15.5%), F2 in 50 (25.7%), F3 in 39 (20.1%), and F4 in 75
(38.7%). All patients had well-preserved liver functions.
2. Diagnostic performances of LS and FT
As shown in Figure 2, the overall mean values of LS (Fig. 2A)
and FT (Fig. 2B) increased in parallel with the increase in fibrosis
stage (all p,0.05). As the fibrosis stage increased from F1 to F4,
the mean value of LS increased from 6.964.2 kPa in F1,
9.765.7 kPa in F2, 12.162.97 kPa in F3, and 21.1610.1 kPa in
F4, while that of FT also increased from 0.1660.17 in F1,
0.3460.18 in F2, 0.660.23 in F3, and 0.7660.19 in F4. LS and
FT were significantly different between F1 and F2 (p=0.035 and
p,0.001), F2 vs. F3 (p=0.034 and p,0.001), and F3 vs. F4
(p,0.001 and p,0.001), respectively.
With regard to the diagnostic performances of LS and FT in the
prediction of histological liver fibrosis, the AUROCs of LS and FT
were 0.873 (95% confidence interval [CI] 0.802–0.944) and 0.903
(95% CI 0.838–0.968) for significant fibrosis (F$2) (Fig. 3A), 0.897
(95% CI 0.846–0.949) and 0.907 (95% CI 0.862–0.952) for
advanced fibrosis (F$3) (Fig. 3B), and 0.910 (95% CI 0.867–
0.953) and 0.866 (0.815–0.918) for cirrhosis (F = 4) (Fig. 3C),
respectively (Table 2). There were no significant differences
between AUROC values of LS and FT (all p.0.05 by Hanley and
McNeil test) [29].
3. Determination of the optimal cutoffs for LS and FT
The most discriminant cutoff values for LS and FT were
determined from the ROC curves to maximize the sum of
sensitivity and specificity [30] (Table 2). LS cutoff values of 8.8,
10.2, and 14.1 kPa generated sensitivity of 78.0%, specificity of
86.7%, NPV of 41.9%, and PPV of 97.0% for F$2; sensitivity of
86.3%, specificity of 90.4%, NPV of 86.3%, and PPV of 90.4% for
F$3; and sensitivity of 84.0%, specificity of 84.9%, NPV of
89.4%, and PPV of 77.8% for F= 4, respectively. Similarly, FT
cutoff scores of 0.32, 0.52, and 0.68 generated sensitivity of 79.3%,
specificity of 93.3%, NPV of 45.2%, and PPV of 98.5% for F$2;
sensitivity of 86.0%, specificity of 90.0%, NPV of 81.8%, and PPV
of 92.5% for F$3; and sensitivity of 80.0%, specificity of 84.0%,
NPV of 87.0%, and PPV of 75.9% for F= 4, respectively.
LS agreed with liver biopsy on the diagnosis of F,2 vs. F$2 in
154 patients (79.3%), F,3 vs. F$3 in 172 patients (88.7%), and
F,4 vs. F = 4 in 164 patients (84.5%), while FT agreed on the
diagnosis of F,2 vs. F$2 in 158 patients (81.4%), F,3 vs. F$3 in
170 patients (87.6%), and F,4 vs. F= 4 in 160 patients (82.5%)
(Table 3). In addition, when using the suggested cutoffs of LS and
FT to diagnose each histological fibrosis stage (F1, F2, F3, and F4),
124 (63.9%) and 123 (63.4%) patients (gray-colored area in
Table 3) were correctly classified consistent with liver biopsy
examination, respectively, and they could avoid liver biopsy
according to the corresponding results by noninvasive methods
(Table 3).
Table 2. Diagnostic performances of LS and FT and their suggested optimal cutoff values.
Method Fibrosis stage AUROC (95% CI) Cutoffs Sensitivity (%) Specificity (%) NPV (%) PPV (%)
LS F$2 0.873 (0.802–0.944) 8.8 kPa 78.0 86.7 41.9 97.0
F$3 0.897 (0.846–0.949) 10.2 kPa 86.3 90.4 86.3 90.4
F=4 0.910 (0.867–0.953) 14.1 kPa 84.0 84.9 89.4 77.8
FT F$2 0.903 (0.838–0.968) 0.32 79.3 93.3 45.2 98.5
F$3 0.907 (0.862–0.952) 0.52 86.0 90.0 81.8 92.5
F=4 0.866 (0.815–0.918) 0.68 80.0 84.0 87.0 75.9
LS, liver stiffness; FT, FibroTest; AUROC, area under the receiver operating characteristics curve; CI, confidence interval; NPV, negative predictive value; PPV, positive
predictive value.
doi:10.1371/journal.pone.0035825.t002
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4. Agreement between LS and FT
Irrespective of matching with histological fibrosis stages, 152
patients (78.3%) showed agreement in fibrosis staging using LS
and FT for noninvasive estimation of F,2 vs. F$2, 158 patients
(81.4%) for F,3 vs. F$3, and 146 patients (75.3%) for F,4 vs.
F = 4. Thus, when LS and FT agreed for noninvasive prediction of
F,2 vs. F$2, F,3 vs. F$3, and F,4 vs. F = 4, these results
agreed with those of liver biopsy examination in 88.8% (134 of 152
patients), 96.8% (153 of 158 patients), and 94.5% (138 of 146
patients), respectively.
Overall agreement between each fibrosis stage (F1, F2, F3, and
F4) estimated by LS and FT was observed in 111 patients. Among
them, 88 patients (79.3%) were correctly classified with reference
to liver biopsy examinations, and they could avoid liver biopsy
based upon concordant results between the two tests (gray-colored
area in Table 4).
5. Discordance between LS and FT
Discordant results between fibrosis stages estimated by LS and
FT were identified in 83 patients (42.8%). On multivariate
analysis, only the presence of histological cirrhosis was identified as
a single significant factor, which showed a negative association
with discordance between LS and FT (p=0.009; odds ratio 0.151,
95% CI 0.036–0.628). Among these patients with discordance
between LS and FT, 41 and 42 patients showed higher fibrosis
stage by LS and by FT, respectively. The baseline characteristics
were compared between these two groups, and none was identified
as a significant factor capable of explaining this difference.
6. Combined use of LS and FT
Based on a previous report by Caste´ra et al. [31], we examined
the diagnostic performance of a combination formula adding LS
to FT (LS+FT). It showed a non-significant trend toward better
AUROC than LS, but was worse than FT in prediction of F$2
(0.885, 95% CI 0.816–0.953) and F$3 (0.905, 95% CI 0.856–
0.955). With regard to prediction of cirrhosis, the combination
formula showed better AUROC (0.915, 95% CI 0.874–0.956)
than LS and FT alone.
Furthermore, we examined the diagnostic performance of
another combination formula multiplying LS by FT (LS6FT),
which showed the best AUROC for prediction of F$2 (0.941,
95% CI 0.908–0.975), F$3 (0.931, 95% CI 0.889–0.974), and
F= 4 (0.929, 95% CI 0.894–0.965), compared to LS, FT, and
LS+FT. The optimized cutoff values of combination formula,
LS+FT and LS6FT, are described in detail in Table 5.
Using the above cutoffs, LS+FT agreed with liver biopsy on the
diagnosis of F,2 vs. F$2 in 164 patients (84.5%), F,3 vs. F$3 in
176 patients (90.7%), and F,4 vs. F= 4 in 169 patients (87.1%),
while LS6FT agreed on the diagnosis of F,2 vs. F$2 in 165
patients (85.1%), F,3 vs. F$3 in 175 patients (90.2%), and F,4
vs. F= 4 in 170 patients (87.6%). Overall, 129 (66.5%) and 130
(67.0%) patients were correctly classified consistent with each
histological fibrosis stage (F1, F2, F3, and F4) using LS+FT and
LS6FT, respectively.
Discussion
FT, a good surrogate marker for liver biopsy, has been widely
studied regarding its usefulness for noninvasive prediction of
fibrosis stage primarily in western populations with HCV infection
[10]. However, only a few investigations have been conducted in
populations with CHB [21,22,23,24,25]. To the best of our
knowledge, we are the first to assess the diagnostic value of FT and
to define new cutoff values for each fibrosis stage optimized for a
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homogenous Asian population with CHB. As there may be a
varied spectrum in diagnostic cutoffs of such noninvasive indices
based on biochemical parameters, even among studies in patients
with the same etiology, a new study to generate standardized,
generalized results in Asian patients with CHB is warranted.
Although the underlying mechanisms of fibrosis progression in
chronic viral hepatitis are expected to be similar, several
differences according to etiology may affect diagnostic accuracy
[32,33]. For example, patients with CHC often have steatosis,
which may influence baseline biochemical parameters, and have
micronodular cirrhosis. Those with CHB more frequently
experience a wide range of fluctuations in necroinflammatory
activity and have macronodular cirrhosis leading to relatively
lower fibrotic contents than those with CHC [33]. These
clinicopathological differences have been suggested to partially
explain the relatively lower cutoff LS values in patients with CHB
than in those with CHC [27]. Hence, in the present study
recruiting Asian patients primarily with CHB, we investigated the
accuracy and applicability of FT, which is the most accurate index
among patients with CHC.
This study has several strengths. First, we prospectively
recruited patients who underwent the baseline blood tests and
LS on the same day as liver biopsy, and the diagnostic
performance of FT was compared to LS, which has already
shown excellent diagnostic value in Asian populations with CHB
[26,34,35,36]. Furthermore, a relatively large number of subjects
from a single center were consecutively enrolled in this study, and
the distribution of our population was homogeneous and
representative of patients with CHB seen in clinical practice.
Therefore, the optimal cutoff values of FT derived from our study
are ultimately expected to be used as reference values for future
studies to elaborate on the role of FT in Asian patients with CHB.
In the present study, the diagnostic performance of FT was
comparable to that of LS for diagnosing fibrosis stages: 0.903 vs.
0.873 for significant fibrosis (F$2), 0.907 vs. 0.897 for advanced
fibrosis (F$3), and 0.866 vs. 0.910 for cirrhosis (F = 4),
respectively. Using the Youden method [30], we suggested FT
cutoff values of 0.32, 0.52, and 0.68 for F$2, F$3, and F= 4,
respectively. All of these values were slightly lower than the
suggested cutoff values for CHB by BioPredictive (0.49, 0.59, and
0.75, respectively). Although several studies have investigated FT
in patients with CHB [21,22,23,24,25], the optimal cutoffs for
each fibrosis stage have not been proposed. Thus, another external
validation is required for our new thresholds for Asian CHB
subjects.
Among subjects where LS and FT agreed with prediction of
F$2, F$3, and F= 4 regardless of matching with histological
examinations, concordance with liver biopsy examination was
observed in 88.8%, 96.8%, and 94.5%, respectively. Furthermore,
overall agreement between each fibrosis stage (F1, F2, F3, and F4)
estimated by LS and FT was observed in 111 patients (57.2%).
Among them, 88 patients (79.3%) were correctly classified with
reference to liver biopsy examinations, and they could avoid liver
biopsy based on the concordant results between the two tests
(Table 4). In contrast to other studies, we demonstrated the
concordance between two tests for noninvasive prediction of each
Table 4. Agreements of histological fibrosis stages among patients who showed concordant results between LS and FT (n = 111).
Total Fibrosis stage estimated by concordant LS and FT results
F1 F2 F3 F4
Fibrosis stage
estimated by
histology LS,8.8 kPa 8.8 kPa#LS,10.2 kPa 10.2 kPa#LS,14.1 kPa LS$14.1 kPa
& FT,0.32 & 0.32#FT,0.52 & 0.52#FT,0.68 & FT$0.68
F1 24 24 0 0 0
F2 21 16 3 1 1
F3 11 1 0 8 2
F4 55 0 0 2 53
Total 111 41 3 11 56
LS, liver stiffness; FT, FibroTest.
doi:10.1371/journal.pone.0035825.t004
Table 5. Diagnostic performances of combination formula using LS and FT and their suggested optimal cutoff values.
Method Fibrosis stage AUROC (95% CI) Cutoffs Sensitivity (%) Specificity (%) NPV (%) PPV (%)
LS+FT F$2 0.885 (0.816–0.953) 8.2 84.8 83.3 50.0 96.5
F$3 0.905 (0.856–0.955) 10.7 93.0 87.5 89.7 91.4
F=4 0.915 (0.874–0.956) 16.8 76.0 94.1 86.2 89.1
LS6FT F$2 0.941 (0.908–0.975) 2.3 82.9 96.7 50.9 99.3
F$3 0.931 (0.889–0.974) 4.7 92.1 87.5 88.6 91.3
F=4 0.929 (0.894–0.965) 9.8 80.0 92.4 88.0 87.0
LS, liver stiffness; FT, FibroTest; AUROC, area under the receiver operating characteristics curve; CI, confidence interval; NPV, negative predictive value; PPV, positive
predictive value.
doi:10.1371/journal.pone.0035825.t005
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fibrosis stage (F1, F2, F3, and F4) along with F$2, F$3, and F= 4.
Such a high level of diagnostic accuracy consistent with previous
investigations is the reason why many experts recommend that
liver biopsy should be avoided for those with concordance between
two noninvasive tests [20,31]. In fact, based on these advantages of
LS and FT, these two markers have been used as the first-line
estimates of fibrosis in France instead of liver biopsy [37].
However, for noninvasive prediction of each fibrosis stage, 83
patients (42.8%) had discordant results between LS and FT, and
liver biopsy should still be strongly considered in such cases,
although several investigators have recently pointed out that the
liver biopsy examination has an error rate of up to 20% in disease
staging even when an experienced physician performs the liver
biopsy examination and an expert pathologist interprets the results
[38,39]. One of the most important methods to minimize such
inherent limitations of liver biopsy examination is to obtain the
reliable biopsy specimens of adequate sizes [40]. From this
viewpoint, we only enrolled patients with so-called reliable biopsy
specimens ($20 mm size) from the beginning of the study.
With regard to discordance between LS and FT, among various
baseline factors, only the presence of histological cirrhosis was
identified as a single significant factor with a negative association
with such discrepancies. Consistent with a previous study [41],
patients with histological cirrhosis have a higher rate of non-
discordance (84.0%) between LS and histology than those without
histological cirrhosis (51.3%, p,0.001). The similar result was
maintained for FT in our study (non-discordance of 80.0% in
patient without histological cirrhosis vs. 47.1%, in subjects with
histological cirrhosis, p,0.001). This negative correlation between
the presence of histological cirrhosis and discordances in the
present study can be explained in part by the different level of
ALT in patients with and without histological cirrhosis (mean
value 43.2 vs. 68.1 IU/L, respectively; p=0.008). Because the
higher ALT has been known as a well-known overestimating
confounder of LS [42] and the same phenomenon was observed
for FT in our cohort (p = 0.018) by linear regression analysis with
adjusting other variables, patients without cirrhosis were more
likely to have discordance between LS (or FT) and liver biopsy.
Accordingly, patients with histological cirrhosis and with relatively
lower ALT level can have a greater likelihood of non-discordance
between LS and FT by diminishing the influence of ALT on LS or
FT. However, further validation studies are required to elucidate
this issue.
Several investigators [25,31] tested the combination formula
with addition of LS to FT (LS+FT), suggesting that it is likely that
a combination of serum biomarkers and LS will complement each
other and enhance accuracy of fibrosis detection. However, this
method did not always show definitely superior results. In the
present study, LS+FT had better AUROC than LS, but was
poorer than FT in prediction of F$2 and F$3, while it had better
AUROCs than LS or FT alone in prediction of F= 4. Next, we
assessed the diagnostic value of LS6FT, which consistently
showed better AUROCs than LS or FT alone in prediction of
F$2, F$3, and F=4. When compared to LS+FT, LS6FT had
better outcomes for diagnosing fibrosis stage. However, further
studies are required to determine which is the better option for
noninvasive diagnosis of fibrosis.
This study is limited in that its design was cross-sectional. It is
not clear whether repeated determination of FT score may be
useful for tracking the progression of fibrosis and related clinical
outcomes, such as occurrence of hepatic decompensation and
HCC in individual patients. Therefore, the diagnostic value for
predicting the subsequent development of cirrhosis and its various
complications with sequential FT measurements during long-term
follow-up must be examined further in a longitudinal study.
Second, our population did not include patients with F0. As our
institute is a tertiary referral hospital and one of the largest medical
centers in Korea, patients with relatively more advanced disease
status are likely to be referred for close follow-up. It might have
resulted in a selection bias and eventually a spectrum bias, since
the diagnostic performance of a given noninvasive test tends to
increase in general in a cohort with the high disease prevalence
and thus the diagnostic performances of LS and FT might have
been overestimated in our cohort accordingly. Therefore, another
independent external validation study in a population with
minimal fibrotic burden should be performed to provide more
generalizable results in patients with CHB-related chronic liver
disease.
In summary, in a prospective study, we first assessed FT in
Asian patients with CHB, demonstrating its comparable diagnostic
accuracy to LS for predicting histological fibrosis stage. The
optimal suggested cutoff values are expected to be useful as
reference values for future studies in Asian patients with CHB.
Our results suggest that combined use of LS and FT could avoid
invasive liver biopsy in most patients with CHB. We hope that
other researchers will evaluate the reproducibility of FT for the
noninvasive diagnosis of fibrosis stage in independent populations.
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